Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.

Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.

A user gained 10-12 kg after starting finasteride but found their estrogen levels to be within the normal range. They are concerned about potential gynecomastia but are reassured by their lab results.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

The user experienced significant hair regrowth with topical finasteride, minoxidil, ketoconazole, and dermarolling, but later faced severe hair shedding after stopping dermarolling and reducing ketoconazole use. Suggestions included switching to oral treatments, resuming dermarolling, and considering lifestyle changes.

User tried dutasteride, topical finasteride, oral minox, dermawounding, saw palmetto, pumpkin seed oil, and ketacozonole for hair loss. Improvement was temporary, now trying RU58841 and seeking help.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.

An 18-year-old woman experiencing hair loss due to stress, possible PCOS, and low vitamin D is concerned about starting 5% minoxidil foam, prescribed by her doctor, due to potential facial hair growth. She is also using a topical steroid for scalp sensitivity and pain.

The user is experiencing severe hair loss after surgery and stress, with thinning all over the head, including the sides and neck. They are unsure if it's due to DUPA or alopecia areata incognita, and doctors have not observed miniaturization.

A 19-year-old female is experiencing significant hair loss, with symptoms including alternating hair colors and thinning body hair. She seeks advice on coping and potential treatments, with suggestions to consult a dermatologist and check thyroid and hormone levels.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

Hair loss discussion involves spironolactone and bicalutamide for women's androgenic alopecia. Focus on effectiveness and side effects.

A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.

A 22-year-old male started taking finasteride a month ago and is seeing some progress in hair loss treatment. He is concerned about high estradiol levels but plans to continue the medication and consult an endocrinologist.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

A 19-year-old male switched from finasteride and minoxidil to dutasteride due to continued hair thinning and is experiencing increased nipple sensitivity and a small lump, raising concerns about gynecomastia. Suggestions include slowing the transition, checking hormone levels, and considering an aromatase inhibitor.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

A woman's experience with Spironolactone as treatment for female pattern hair loss, including the effects of increasing dosage and her doctor's recommendation to try finasteride if no results are seen after 6 months. Other users have also shared their experiences with using finasteride for this condition.